Calcium Channel Blockers in Hypertension

Hypertension: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2007, Pages 268-285

  Zanchetti, Alberto ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956126114     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3053-9.50028-7     Document Type: Chapter

References (115)

1. Fleckenstein A Calcium Antagonism in Heart and Smooth Muscle 1983, Wiley & Sons, New York.
2. Triggle DJ Mechanisms of action of calcium channel antagonists. Calcium Antagonists in Clinical Medicine 2002, 1-32. Hanley & Belfus, Philadelphia. 3rd ed. M. Epstein (Ed.).
3. Godfraind T Calcium Channel Blockers 2004, Birkhauser, Basel.
4. Meredith PA, Elliott HL Dihydropyridine calcium channel blockers: Basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 2004, 22:1641-1648.
5. Mancia G, Parati G Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment with calcium antagonists. Calcium Antagonists in Clinical Medicine 2002, 117-137. Hanley & Belfus, Philadelphia. 3rd ed. M. Epstein (Ed.).
6. Leonetti G, Sala C, Bianchini C, et al. Antihypertensive and renal effects of oral administration of verapamil. Eur J Clin Pharmacol 1980, 18:375-382.
7. Olivari MT, Bartorelli C, Polese A, et al. Treatment of hypertension with nifedipine, a calcium antagonist agent. Circulation 1979, 59:1056-1062.
8. Epstein M Calcium antagonists in the management of hypertension. Calcium Antagonists in Clinical Medicine 2002, 292-313. Hanley & Belfus, Philadelphia. 3rd ed. M. Epstein (Ed.).
9. Chobanian AV, Bakris GL, Black HR, the National High Blood Pressure Education Program Coordinating Committee, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003, 289:2560-2572.
10. Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1059.
11. World Health Organization-International Society of Hypertension Writing Group World Health Organization-International Society of Hypertension statement on management of hypertension. J Hypertens 2003, 21:1983-1992.
12. Burlando G, Sanchez RA, Ramos FH, et al. Latin American consensus on diabetes mellitus and hypertension. J Hypertens 2004, 22:2229-2241.
13. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study: Final results. JAMA 1993, 279:713-724.
14. Materson BJ, Reda DJ, Cushman WC Department of Veterans Affairs single-drug therapy of hypertension study: Revised figures and new data. Am J Hypertens 1995, 8:189-192.
15. Brewster LM, van Montfrans GA, Kleijnen J Systematic review: Antihypertensive drug therapy in black patients. Ann Intern Med 2004, 141:614-627.
16. Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: How to combine drugs. J Hum Hypertens 2003, 17:81-86.
17. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004, 18:139-185.
18. Leonetti G, Cuspidi C, Sampieri L, et al. Comparison of cardiovascular, renal, and humoral effects of acute administration of calcium channel blockers in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 1982, 4(Suppl 3):19-24.
19. Lund-Johansen P Hemodynamic effects of calcium antagonists in hypertension. Calcium Antagonists in Clinical Medicine 2002, 315-335. Hanley & Belfus, Philadelphia. 3rd ed. M. Epstein (Ed.).
20. Furberg C, Psaty B, Meyer J Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1325-1331.
21. Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995, 274:620-625.
22. Pahor M, Guralnik J, Corti M, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995, 43:1191-1197.
23. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension Effects of calcium antagonists on the risk of coronary heart disease, cancer and bleeding. J Hypertens 1997, 15:105-115.
24. Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 2004, 292:2849-2859.
25. Gong L, Zhang W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996, 14:1237-1245.
26. Staessen J, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension in Europe. Lancet 1997, 350:757-764.
27. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension (Syst-China). J Hypertens 1998, 16:1823-1829.
28. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001, 345:851-860.
29. Lubsen J, Wagener G, Kirwan B-A, et al. Effects of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: The ACTION trial. J Hypertens 2005, 23:641-648.
30. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005, 23:2157-2172.
31. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS), a randomized controlled trial. JAMA 1996, 276:785-791.
32. Agabiti-Rosei E, Dal Palu C, Leonetti G, for the VHAS investigators, et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens 1997, 15:1337-1344.
33. Zanchetti A, Agabiti-Rosei E, Dal Palu C, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term randomised treatment with either verapamil or chlorthalidone on intima-media thickness. J Hypertens 1998, 16:1667-1676.
34. Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity-the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
35. National Intervention Cooperative Study in Elderly Hypertensives Study Group Randomized double-blind comparison of a calcium-antagonist and a diuretic in elderly hypertensives. Hypertension 1999, 34:1129-1133.
36. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium-antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
37. Brown M, Palmer C, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blockers or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
38. Agodoa LY, Appel L, Bakris GL, for the African American Study of Kidney Disease and Hypertension (AASK) Study Group, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001, 285:2719-2728.
39. Wright JT, Bakris GL, Green T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK Trial. JAMA 2002, 288:2421-2431.
40. Zanchetti A, Bond M, Hennig M, et al. Calcium-antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation 2002, 106:2422-2427.
41. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002, 288:2981-2997. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
42. Black HR, Elliott WJ, Grandis G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
43. Malacco E, Mancia G, Rappelli A, for the SHELL Investigators, et al. Treatment of isolated systolic hypertension: The SHELL study results. Blood Press 2003, 12:160-167.
44. Pepine CJ, Handberg EM, Cooper-De Hoff RM, et al. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST). A randomized controlled trial. JAMA 2003, 290:2805-2819.
45. Dahlof B, Sever PS, Poulter NR, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005, 366:907-913.
46. Estacio R, Jeffers B, Hiatt W, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
47. Tatti P, Pahor M, Byington RD, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597-603.
48. Schrier R, Estacio R, Esler A, et al. Effect of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
49. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: The Japan Multicenter Investigation for Cardiovascular Disease-B (JMIC-B) randomized trial. Hypertens Res 2004, 27:181-191.
50. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004, 363:2022-2031.
51. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomized trials. Lancet 2003, 362:1527-1535. Blood Pressure Lowering Treatment Trialists' Collaboration.
52. Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: A meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004, 17:817-822.
53. Dens J, Desmet W, Coussement P, et al. Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). Am J Cardiol 2001, 87:28-33.
54. Pitt B, Byington R, Furberg C, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000, 102:1503-1510.
55. Zanchetti A Evidence-based medicine in hypertension: What type of evidence?. J Hypertens 2005, 23:1113-1120.
56. Poole Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial. Lancet 2004, 364:849-857.
57. Nissen SE, Turzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT Study. A randomized controlled trial. JAMA 2004, 292:2217-2226.
58. Messerli FH Vasodilatory edema: A common side effect of antihypertensive therapy. Am J Hypertens 2001, 14:978-979.
59. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
60. Wiklund I, Hailing K, Ryden-Bergsten T, et al. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) Study. Blood Press 1997, 6:357-362.
61. Leonetti G, Magnani B, Pessina AC, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002, 15:932-940.
62. Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003, 21:1003-1010.
63. Zanchetti A, Omboni S, La Commare P, et al. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol 2001, 38:642-650.
64. Pahor M, Guralnik J, Salive M, et al. Do calcium channel blockers increase the risk of cancer?. Am J Hypertens 1996, 9:695-699.
65. Pahor M, Guralnik J, Ferrucci L, et al. Calcium channel blockade and incidence of cancer in aged populations. Lancet 1996, 348:493-497.
66. Pahor M, Guralnik J, Furberg C, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996, 347:1061-1065.
67. Zanchetti A, Ruilope LM Antihypertensive treatment in patients with type-2 diabetes mellitus: What guidance from recent controlled randomized trials?. J Hypertens 2002, 20:2099-2110.
68. Opie LH, Schall R Old antihypertensives and new diabetes. J Hypertens 2004, 22:1453-1458.
69. Messerli FH, Grossman E, Leonetti G Antihypertensive therapy and new onset diabetes. J Hypertens 2004, 22:1845-1847.
70. Eberly LE, Cohen JD, Prineas R, et al. Impact of incident diabetes and incident non fatal cardiovascular disease on 18-year mortality: The Multiple Risk Factor Intervention Trial experience. Diabetes Care 2003, 26:848-854.
71. Epstein M, Waeber B Fixed-dose combination therapy with calcium antagonists. Calcium Antagonists in Clinical Medicine 2002, 713-730. Hanley & Belfus, Philadelphia. 3rd ed. M. Epstein (Ed.).
72. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomised double-blind intervention trial. J Hypertens 2003, 21:875-886.
73. Brenner B, Cooper M, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
74. Leonetti G, Gradnik R, Terzoli L, et al. Effect of single and repeated doses of the calcium antagonist felodipine on blood pressure, renal function, electrolytes and water balance, and renin-angiotensin-aldosterone system in hypertensive patients. J Cardiovasc Pharmacol 1986, 8:1243-1248.
75. Pevahouse JB, Markandu ND, Cappuccio FP, et al. Long term reduction in sodium balance: Possible additional mechanism whereby nifedipine lowers blood pressure. BMJ 1990, 301:580-584.
76. Weir MR The clinical utility of calcium antagonists in renal transplant recipients. Calcium Antagonists in Clinical Medicine 2002, 603-628. Hanley & Belfus, Philadelphia. 3rd ed. M. Epstein (Ed.).
77. Voyaki SM, Staessen JA, Thijs L, et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001, 19:511-519.
78. Zanchetti A The antiatherogenic effects of antihypertensive treatment: Trials completed and ongoing. Curr Hypertens Rep 2001, 3:350-359.
79. Ciulla MM, Paliotti R, Ferrero S, et al. Assessment of carotid plaque composition in hypertensive patients by ultrasonic tissue characterization: A validation study. J Hypertens 2002, 20:1589-1596.
80. Paliotti R, Ciulla MM, Hennig M, et al. Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol. An echoreflectivity study. J Hypertens 2005, 23:1203-1209.
81. Simon A, Gariepy J, Moyse D, et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001, 103:2949-2954.
82. Zanchetti A, Bond MG, Hennig M, et al. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: Further results of the European Lacidipine Study on Atherosclerosis (EISA). J Hypertens 2004, 22:1201-1212.
83. Motro M, Shemesh J Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001, 37:1410-1413.
84. Lichtlen PR, Hugenholtz PG, Raffenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine: Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990, 335:1109-1113.
85. Taddei S, Virdis A, Ghiadoni L, et al. Effect of calcium antagonist or beta-blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 1998, 16:1913-1916.
86. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004, 292:2396-2398.
87. Cuspidi C, Leonetti G, Zanchetti A Left ventricular hypertension regression with antihypertensive treatment: Focus on candesartan. Blood Press 2003, 12(Suppl 2):5-15.
88. Schmieder RE, Schlaich MF, Klingbell AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1998). Nephrol Dial Transplant 1998, 13:564-569.
89. Jennings GL, Wong J Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. Handbook of Hypertension, vol 18: Assessment of Hypertensive Organ Damage 1997, 184-229. Elsevier, Amsterdam. L. Hansson, W.H. Birkenhager (Eds.).
90. Tepstra WL, May JF, Smith AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: The ELVERA trial. J Hypertens 2001, 19:303-309.
91. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001, 104:1248-1254.
92. Zanchetti A, Ruilope LM, Cuspidi C, et al. Comparative effects of the ACE inhibitor fosinopril and the calcium antagonist amlodipine on left ventricular hypertrophy and urinary albumin excretion in hypertensive patients: Results of FOAM, a multicenter European study [abstract]. J Hypertens 2001, 19(Suppl 2):S92.
93. Agabiti-Rosei E, Trimarco B, Muiesan ML, on behalf of the ELSA echocardiographic substudy group, et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005, 23:1091-1098.
94. Ciulla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: Results of a randomized trial. Circulation 2004, 110:552-557.
95. Benetos A, Zureik M, Morcet J, et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000, 35:673-680.
96. London GM, Safar ME Arterial compliance and effect of calcium antagonists. Calcium Antagonists in Clinical Medicine 2003, 345-362. Hanley & Belfus, Philadelphia. 3rd ed. M. Epstein (Ed.).
97. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264. SHEP Collaborative Research Group.
98. Prince MJ, Bird AS, Blizard RA, Mann AH Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 1996, 312:801-805.
99. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041. PROGRESS Collaborative Study Group.
100. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with hypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch Intern Med 2002, 162:2046-2052.
101. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and non diabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003, 41:431-436.
102. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetics patients: Results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000, 18:1671-1675.
103. Turnbull F, Neal B, Algert C Effect of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes: Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419. for the Blood Pressure Lowering Treatment Trialists' Collaboration.
104. Bakris GL, Gaxiola E, Messerli FH, et al. Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril Study. Hypertension 2004, 44:637-642.
105. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1956.
106. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999, 340:677-684.
107. Estacio RO, Jeffers BW, Gifford N, Schrier RW Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(Suppl 2):B54-B64.
108. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003, 139:244-252.
109. Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001, 19:1871-1876.
110. Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992, 42:452-458.
111. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2001, 1. CD002252.
112. Sibai B, Dekker G, Kupferminc M Pre-eclampsia. Lancet 2005, 365:785-799.
113. Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: Meta-analysis. BMJ 2003, 327:1-10.
114. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine in Survival Evaluation Study Group. N Engl J Med 1996, 335:1107-1114.
115. Cabell CH, Trichon BH, Valzquez EJ, et al. Importance of echocardiography in patients with severe nonischemic heart failure: The second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. Am Heart J 2004, 147:151-157.